Relapsed/Refractory Follicular Lymphoma at #ASH24
event presence logo
Bispecific Antibodies:

A Playbook for Relapsed/Refractory Follicular Lymphoma CME/CNE/CPE

Marriott Marquis San Diego Marina 
Friday, December 6, 2024 | 03:30 PM - 05:00 PM PT
Supported by an independent educational grant from Genmab US, Inc. and AbbVie.

overview

This live panel discussion will focus on the advancing field of bispecific antibodies in third-line relapsed/refractory follicular lymphoma. Experts in the field of follicular lymphoma, with the added perspective of a patient advocate, will review best practices for assessing and applying the latest data on bispecific antibodies, as well as strategies to enhance shared decision-making and patient-centered care.

A Friday Satellite Symposium on Hematology, preceding the 66th ASH Annual Meeting and Exposition.

Enhance Your Experience With MedChallenge!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

faculty

MODERATOR

Joshua Brody, MD

Director, Lymphoma Immunotherapy Program 

​Icahn School of Medicine at Mount Sinai

​Hess Center for Science and Medicine

​New York City, New York

PANELIST

Krish Patel, MD

Director, Lymphoma Program

​Director, Hematologic Malignancies and Cellular Therapy

​Center for Blood Disorders and Cellular Therapy

​Swedish Cancer Institute

​Seattle, Washington

PANELIST

Lorna Warwick

Chief Executive Officer

​Lymphoma Coalition

​Mississauga, Ontario, Canada

AGENDA

3:00 pm

Meal and Registration

3:30 pm

The Lineup and Who’s on Deck: Differentiating Between Current and Emerging Bispecific Antibodies

Joshua Brody, MD

3:35 pm

Welcome and Introductions

Joshua Brody, MD

3:55 pm

The Scouting Report: Voicing the Patient Perspective

Krish Patel, MD; Lorna Warwick

4:15 pm

Expert Fielding: Bispecific Antibodies in the Relapsed FL Clinic

All Faculty

4:40 pm

Bottom of the 9th: The Future of Bispecifics in FL

Krish Patel, MD

4:50 pm

Closing Remarks

Joshua Brody, MD

4:55 pm

Audience Q&A

Joshua Brody, MD
backstage pass
Enhance Your Virtual Experience With Backstage Pass! Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.
*Video encouraged*

LOCATION

Marriott Marquis San Diego Marina 

333 W Harbor Drive, San Diego, CA , 92101

Room: Grand Ballroom 11-13

GOAL STATEMENT

The goal of this activity is for learners to be better able to differentiate between bispecific antibodies used in the treatment of R/R FL and integrate evidence-based and patient-centered treatment strategies.

TARGET AUDIENCE

This activity is intended for hematologists and oncologists, oncology nurses, oncology nurse practitioners, physician assistants, oncology pharmacists, and other healthcare professionals who treat patients with follicular lymphoma (FL).

LEARNING OBJECTIVES

Upon completion of this activity, participants will:[break][break] Have increased knowledge regarding the [LIST] [ITEM]Key differences between current and emerging bispecific antibodies used to treat R/R FL[/LIST] [break] Have greater competence related to [LIST] [ITEM]Managing therapy for R/R FL with bispecific antibodies [ITEM]Managing AEs of bispecific antibody therapy[/LIST] [break] Demonstrate greater confidence in their ability to [LIST] [ITEM]Incorporate patient-centered strategies when caring for patients receiving bispecific antibodies for R/R FL [/LIST]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
accreditation logo
medscape logo
[bold]For Physicians[/bold][break] Medscape, LLC designates this live activity for a maximum of 1.50 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [break][break] [bold]​​For Nurses[/bold][break] ​Awarded ​1.50​ contact hour(s) of nursing continuing professional development for RNs and APNs; ​1.50​ contact hours are in the area of pharmacology. [break][break] [bold]For Pharmacists[/bold][break] Medscape designates this continuing education activity for ​1.50​ contact hour(s) (​0.150​ CEUs) (Universal Activity Number: ​JA0007105-0000-24-174-L01-P​).
© 2024 MedscapeLIVE! All Rights Reserved | Medscape Education Terms of Service | Privacy Policy